Here, we perform a study in an independent cohort of early-stage and locally advanced breast cancer patients to forecast tumor response to NAT and assess the stability of a previously validated biophysical simulation platform.
Here, we perform a study in an independent cohort of early-stage and locally advanced breast cancer patients to forecast tumor response to NAT and assess the stability of a previously validated biophysical simulation platform.
Here we performed a proof-of-concept study using trastuzumab emtansine (TDM1), a targeted drug for HER2-enriched breast cancer, to demonstrate how biophysical modeling can support dose selection in phase I clinical trials.
Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) is largely dependent on breast cancer subtype, but no clinical-grade model exists to predict response and guide selection of treatment. A biophysical simulation of response to NAC…
Abstract Background: Race-related differences in breast cancer incidence and clinical outcome have been well documented, with many studies focusing on socioeconomic determinants contributing to African American (AA) breast cancer patients having higher mortality rates. Far less is understood about the…
Abstract Tumor heterogeneity is known to play a key role in drug response and resistance. However, knowledge of tumor heterogeneity is largely limited to genetics and biopsy samples representing one region of the tumor. The study of spatial tumor heterogeneity…
Abstract Background: The 21-gene (Oncotype DX) recurrence score (RS) has been utilized as a prognostic assay in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. The results stratify patients into low-, mid- and high-risk…
Abstract While most cancer patients are treated at community hospitals, specialized equipment, diagnostic tests, and therapeutic regimens are generally validated at academic settings. Here we present a novel approach to precision medicine to improve outcomes in breast cancer care in…
Abstract Background: During the I-SPY2 clinical trial, ganitumab (G) immunotherapy (IO) was co-administered with metformin (GM) to counteract G-induced hyperglycemia. The GM + standard of care (SOC) combination showed promising results but did not meet the statistical threshold for phase…
Abstract: Breast cancer is a highly heterogeneous disease. Prognosis and treatment are usually decided based on the expression of 3 molecular markers; one being the human epidermal growth factor receptor 2 (HER2). Classification of HER2 tumors generally follows a binary…
SOLUTIONS
RESOURCES
©SimBioSys